Premium
Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV
Author(s) -
Bril Vera,
Katzberg Hans,
Donofrio Peter,
Banach Marta,
Dalakas Marinos C.,
Deng Chunqin,
Hanna Kim,
Hartung HansPeter,
Hughes Richard A.C.,
Latov Norman,
Merkies Ingemar S.J.,
Van Doorn Pieter A.
Publication year - 2009
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21236
Subject(s) - chronic inflammatory demyelinating polyneuropathy , placebo , medicine , polyradiculoneuropathy , multifocal motor neuropathy , crossover study , electrophysiology , anesthesia , clinical endpoint , randomized controlled trial , guillain barre syndrome , immunology , antibody , mismatch negativity , pathology , alternative medicine , electroencephalography , psychiatry
Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) received immune globulin intravenous, 10% caprylate/chromatography purified (IGIV‐C, Gamunex; n = 59) or placebo ( n = 58) every 3 weeks for up to 24 weeks (first period) in a randomized, double‐blind, parallel‐group, response‐conditional, crossover study. Motor and sensory nerves were assessed at baseline and endpoint/week 24. A nonsignificant trend toward improvement in the proximal amplitude of the most severely affected motor nerve was observed with IGIV‐C (0.69 ± 1.86 mV) versus placebo (0.47 ± 2.29 mV), and a greater improvement of 1.08 ± 2.15 mV with IGIV‐C versus 0.46 ± 2.03 mV with placebo ( P = 0.089) was observed with exclusion of data from Erb's point stimulation. Greater improvements from baseline favoring IGIV‐C were observed for 127/142 electrophysiologic parameters. The averaged motor amplitudes from all motor nerves significantly improved with IGIV‐C versus placebo [treatment difference, 0.62 mV; 95% confidence interval (CI), 0.05, 1.20; P = 0.035], and conduction block decreased significantly (treatment difference, −5.54%; 95% CI, −10.43, −0.64; P = 0.027), particularly in the lower limbs. Overall, the data suggest that IGIV‐C improves electrophysiologic parameters in CIDP. Muscle Nerve, 2009